Serina Therapeutics (SER) 10-Q 14 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 08, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	1-38519
Entity Registrant Name	AgeX Therapeutics, Inc.
Entity Central Index Key	0001708599
Entity Tax Identification Number	82-1436829
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1101 Marina Village Parkway
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	Alameda
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94501
City Area Code	(510)
Local Phone Number	671-8370
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AGE
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,951,261

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 261	$ 645
Accounts and grants receivable, net	6	4
Prepaid expenses and other current assets	1,083	1,804
Total current assets	1,350	2,453
Restricted cash	50	50
Intangible assets, net	673	738
Convertible note receivable	10,204
TOTAL ASSETS	12,277	3,241
Current liabilities:
Accounts payable and accrued liabilities	961	1,034
Loans due to Juvenescence, net of debt issuance costs, current portion	22,943	7,646
Warrant liability		180
Insurance premium liability and other current liabilities	371	1,077
Total current liabilities	24,505	10,078
Loans due to Juvenescence, net of debt issuance costs, net of current portion	10,068	10,478
TOTAL LIABILITIES	34,573	20,556
Commitments and contingencies (Note 11)
Stockholders’ deficit:
Preferred stock, $0.0001 par value, 5,000 shares authorized; none issued and outstanding
Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding	4	4
Additional paid-in capital	99,977	98,994
Accumulated deficit	(122,156)	(116,210)
Total AgeX Therapeutics, Inc. stockholders’ deficit	(22,175)	(17,212)
Noncontrolling interest	(121)	(103)
Total stockholders’ deficit	(22,296)	(17,315)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	12,277	3,241
Related Party [Member]
Current liabilities:
Related party payables, net	$ 230	$ 141

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	37,951,261	37,949,196
Common stock, shares outstanding	37,951,261	37,949,196

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
REVENUES
Revenues	$ 9	$ 12	$ 19	$ 17
Cost of sales	5	6	6	7
Gross profit	4	6	13	10
OPERATING EXPENSES
Research and development	160	259	334	655
General and administrative	1,730	1,338	3,723	2,998
Total operating expenses	1,890	1,597	4,057	3,653
Loss from operations	(1,886)	(1,591)	(4,044)	(3,643)
OTHER EXPENSE, NET:
Interest expense, net	(792)	(863)	(1,892)	(1,434)
Change in fair value of warrants	(5)	(168)	(35)	(255)
Other income, net	4	4	7	7
Total other expense, net	(793)	(1,027)	(1,920)	(1,682)
NET LOSS	(2,679)	(2,618)	(5,964)	(5,325)
Net loss attributable to noncontrolling interest	10		18	1
NET LOSS ATTRIBUTABLE TO AGEX	$ (2,669)	$ (2,618)	$ (5,946)	$ (5,324)
NET LOSS PER COMMON SHARE: BASIC AND DILUTED
BASIC	$ (0.07)	$ (0.07)	$ (0.16)	$ (0.14)
DILUTED	$ (0.07)	$ (0.07)	$ (0.16)	$ (0.14)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
Basic	37,951	37,943	37,950	37,943
DILUTED	37,951	37,943	37,950	37,943

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
NET LOSS	$ (2,679)	$ (2,618)	$ (5,964)	$ (5,325)
Less: Comprehensive loss attributable to noncontrolling interest	10		18	1
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGEX COMMON STOCKHOLDERS	$ (2,669)	$ (2,618)	$ (5,946)	$ (5,324)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2021	$ 4	$ 93,912	$ (105,748)	$ (43)	$ (11,875)
Balance, shares at Dec. 31, 2021	37,941
Fair value of liability classified warrants issued		3,325			3,325
Stock-based compensation		437			437
Net loss			(5,324)	(1)	(5,325)
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes		(2)			(2)
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares	4
Issuance of warrants		178			178
Balance at Jun. 30, 2022	$ 4	97,850	(111,072)	(44)	(13,262)
Balance, shares at Jun. 30, 2022	37,945
Balance at Mar. 31, 2022	$ 4	96,903	(108,454)	(44)	(11,591)
Balance, shares at Mar. 31, 2022	37,943
Fair value of liability classified warrants issued		750			750
Stock-based compensation		198			198
Net loss			(2,618)		(2,618)
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes		(1)			(1)
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares	2
Balance at Jun. 30, 2022	$ 4	97,850	(111,072)	(44)	(13,262)
Balance, shares at Jun. 30, 2022	37,945
Balance at Dec. 31, 2022	$ 4	98,994	(116,210)	(103)	(17,315)
Balance, shares at Dec. 31, 2022	37,949
Fair value of liability classified warrants issued		879			879
Stock-based compensation		105			105
Net loss			(5,946)	(18)	(5,964)
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes		(1)			(1)
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares	2
Balance at Jun. 30, 2023	$ 4	99,977	(122,156)	(121)	(22,296)
Balance, shares at Jun. 30, 2023	37,951
Balance at Mar. 31, 2023	$ 4	99,589	(119,487)	(111)	(20,005)
Balance, shares at Mar. 31, 2023	37,951
Fair value of liability classified warrants issued		353			353
Stock-based compensation		35			35
Net loss			(2,669)	(10)	(2,679)
Balance at Jun. 30, 2023	$ 4	$ 99,977	$ (122,156)	$ (121)	$ (22,296)
Balance, shares at Jun. 30, 2023	37,951

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
OPERATING ACTIVITIES:
Net loss attributable to AgeX	$ (2,669)	$ (2,618)	$ (5,946)	$ (5,324)
Net loss attributable to noncontrolling interest	(10)		(18)	(1)
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:
Change in fair value of warrants	5	168	35	255
Amortization of intangible assets	32	33	65	66
Amortization of debt issuance costs			1,976	1,355
Stock-based compensation			105	437
Changes in operating assets and liabilities:
Accounts and grants receivable			(2)	13
Prepaid expenses and other current assets			721	614
Interest on convertible note receivable			(204)
Accounts payable and accrued liabilities			(96)	(207)
Related party payables			186	65
Insurance premium liability			(711)	(653)
Other current liabilities			5	(2)
Net cash used in operating activities			(3,884)	(3,382)
INVESTING ACTIVITIES:
Cash advanced on convertible note receivable			(10,000)
Net cash used in investing activities			(10,000)
FINANCING ACTIVITIES:
Drawdown on loan facilities from Juvenescence			13,500	3,500
Net cash provided by financing activities			13,500	3,500
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH			(384)	118
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
At beginning of the period			695	634	$ 634
At end of the period	$ 311	$ 752	$ 311	$ 752	$ 695

Organization, Business Overview

Organization, Business Overview and Liquidity	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Business Overview and Liquidity	1. Organization, Business Overview and Liquidity AgeX Therapeutics, Inc. (“AgeX”) was incorporated in January 2017 in the state of Delaware. AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions. AgeX’s proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows AgeX to utilize telomerase-expressing regenerative pluripotent stem cells (“PSCs”) for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. AgeX’s main technology platforms and product candidates are: ● PureStem ® ● UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells; ● AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes; ● AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia; and ● Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair. Restructuring Plans During March 2023, AgeX borrowed $ 10,000,000 10 10,000,000 No definitive agreement regarding a merger between AgeX and Serina has been negotiated or executed nor has the merger been approved by the respective boards of directors of AgeX and Serina. Further, a merger cannot be consummated unless approved by the stockholders of AgeX and Serina. Accordingly, there is no assurance that AgeX and Serina will reach agreement on the terms of a merger or that, if such an agreement is reached, the stockholders of AgeX and Serina will approve the merger. Definitive agreements regarding the Reverse Bio Financing and a Reverse Bio spinoff have not yet been executed, nor has AgeX’s board of directors approved the Reverse Bio spinoff. Accordingly, there is a risk that the Reverse Bio Financing and the Reverse Bio spinoff may never be consummated. Emerging Growth Company AgeX is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012. Going Concern AgeX primarily finances its operations through loans from its largest stockholder Juvenescence. AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $ 122.2 Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have adopted operating plans and budgets to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those operating plans and budgets, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $ 0.3 4 Liquidity and Impact of COVID-19 In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in out-licensing its technologies and development of its product candidates. Although AgeX has been able to reduce its operating expenses, with the exception of certain non-recurring expenses incurred related to the possible merger between AgeX and Serina, by eliminating internal research and development activities and focusing instead on outsourcing research and development and seeking licensing arrangements for AgeX technologies, this approach has also made it more difficult for AgeX to make progress in developing its target product candidates and technologies, which in turn may make it more difficult for AgeX to raise capital. The availability of financing also may be adversely impacted by the COVID-19 pandemic to the extent it disrupts aspects of AgeX’s operations. The extent to which the ongoing COVID-19 pandemic will ultimately impact AgeX’s business, results of operations, financial condition, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside AgeX’s control. The unavailability or inadequacy of financing to meet future capital needs could force AgeX to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its stockholders. AgeX cannot assure that adequate financing will be available on favorable terms, if at all.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of Presentation and Summary of Significant Accounting Policies The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by U.S. GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of AgeX’s financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Principles of consolidation The consolidated financial statements include the accounts of AgeX and its subsidiaries in which AgeX has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which AgeX is the primary beneficiary (as described in more detail below). For consolidated entities where AgeX has less than 100 AgeX assesses whether it is the primary beneficiary of a variable interest entity (“VIE”) at the inception of the arrangement and at each reporting date. This assessment is based on its power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and AgeX’s obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. If the entity is within the scope of the variable interest model and meets the definition of a VIE, AgeX considers whether it must consolidate the VIE or provide additional disclosures regarding its involvement with the VIE. If AgeX determines that it is the primary beneficiary of the VIE, AgeX will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event. For entities AgeX holds as an equity investment that are not consolidated under the VIE model, AgeX will consider whether its investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model. AgeX has three subsidiaries, Reverse Bio, ReCyte Therapeutics, Inc. (“ReCyte”), and NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”). Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTR TM TM 94.8 50 Consolidation Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of AgeX’s embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. The financial information for private companies may not be available and, even if available, that information may be limited and/or unreliable. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected. See Note 6, Warrant Liability Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject AgeX to concentrations of risk consist principally of cash equivalents and a convertible note receivable. AgeX maintains its cash deposits in Federal Deposit Insurance Corporation insured financial institutions within the federally insured limits. Even if balances were to exceed the federally insured limits, AgeX does not believe that it would be exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. AgeX also monitors the creditworthiness of the borrower of the convertible promissory note. AgeX believes that any concentration of credit risk in a convertible note receivable was mitigated in part by (i) AgeX’s right to convert loan amounts owed to AgeX into shares of equity securities of the borrower in the event the borrower completes a financing in at least a designated amount, and (ii) AgeX’s right to tender the convertible note receivable to a lender to settle a convertible note payable. See Notes 4, Convertible Note Receivable Related Party Transactions Product candidates developed by AgeX and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by AgeX or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on AgeX. Fair value measurements of financial instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date. The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. The convertible note receivable is reported at fair value as it bears market rates of interest. Fair values for the AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, Fair Value Measurements and Disclosures ● Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 – Inputs to the valuation methodology include observable quoted prices (other than quoted market prices included within Level 1) for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments. ● Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value. In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items. The discounted conversion prices triggered by certain qualified events in the Serina Note and the $ 10 Convertible Note Receivable Related Party Transactions Subsequent Events The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times. The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations are discussed further in Note 6, Warrant Liability See Note 6, Warrant Liability Cash, cash equivalents, and restricted cash In accordance with Accounting Standards Update (“ASU”) 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash Schedule of Cash, Cash Equivalents and Restricted Cash June 30, 2023 (unaudited) December 31, 2022 Cash and cash equivalents $ 261 $ 645 Restricted cash (1) 50 50 Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows $ 311 $ 695 (1) Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. Long-lived intangible assets, net Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 10 Selected Balance Sheet Components Impairment of long-lived assets AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consists entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of June 30, 2023, there has been no impairment of long-lived assets. Leases AgeX accounts for leases in accordance with ASU 2016-02, Leases Codification Improvements to Topic 842, Leases, Leases (Topic 842): Targeted Improvements, (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less. AgeX leases office space in Alameda, California. For 2022 base monthly rent was $ 1,074 844 Accounting for warrants AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock Related Party Transactions Warrant Liability Revenue recognition AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. ESI BIO Research Products – Arrangements with multiple performance obligations – Research and development Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and contractors, sponsored research agreements with certain universities, and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations. General and administrative General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Basic and diluted net loss per share attributable to common stockholders Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any. For the three and six months ended June 30, 2023 and 2022, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive. The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Stock options 3,261 3,274 3,261 3,333 Warrants (1) 13,246 9,794 13,013 8,099 Restricted stock units - 12 1 13 (1) As of June 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase 12,503,522 10,323,105 Related Party Transactions Reclassifications Certain reclassifications have been made to the prior period’s condensed consolidated interim financial statements to conform to current year presentation. Additionally, certain financial information is presented on a rounded basis, which may cause minor differences. Recently adopted accounting pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In March 2022, the FASB issued ASU No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures On July 14, 2023, the FASB issued ASU No. 2023-02, P resentation of Financial Statements (Topic 205), Income Statement – Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation

Selected Balance Sheet Componen

Selected Balance Sheet Components	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Selected Balance Sheet Components	3. Selected Balance Sheet Components Intangible assets, net At June 30, 2023 and December 31, 2022, intangible assets, primarily consisting of acquired IPR&D and patents, and accumulated amortization were as follows (in thousands): Schedule of Intangible Assets, Net June 30, 2023 (unaudited) December 31, 2022 Intangible assets $ 1,312 $ 1,312 Accumulated amortization (639 ) (574 ) Total intangible assets, net $ 673 $ 738 AgeX recognized $ 32,000 65,000 33,000 66,000 Amortization of intangible assets for periods subsequent to June 30, 2023 is as follows (in thousands): Schedule of Amortization Assets Year Ending December 31, Amortization Expense 2023 $ 66 2024 131 2025 131 2026 132 Thereafter 213 Total $ 673 Accounts payable and accrued liabilities At June 30, 2023 and December 31, 2022, accounts payable and accrued liabilities were comprised of the following (in thousands): Schedule of Accounts Payable and Accrued Liabilities June 30, 2023 (unaudited) December 31, 2022 Accounts payable $ 506 $ 568 Accrued compensation 199 193 Accrued vendors and other expenses 256 273 Total accounts payable and accrued liabilities $ 961 $ 1,034

Convertible Note Receivable

Convertible Note Receivable	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Convertible Note Receivable	4. Convertible Note Receivable On March 15, 2023, AgeX and Serina entered into a Convertible Note Purchase Agreement (the “Serina Note Purchase Agreement”), pursuant to which AgeX lent to Serina an aggregate principal amount of $ 10,000,000 7 In connection with the issuance of the Serina Note, AgeX is entitled to elect one member to the board of directors of Serina and receive certain information and inspection rights as well as participation rights for subsequent equity issuances. The principal balance of the Serina Note with accrued interest will automatically convert into Serina preferred stock if Serina raises at least $ 25,000,000 80 105,000,000 20 Derivatives and Hedging—Embedded Derivatives 20 Interest (income) expense, net Other (income) expense, net AgeX may (i) at its election, upon a change of control (as defined in the Serina Note), convert the Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the Serina Note, plus interest, or (b) into the highest ranking shares of Serina then issued at a conversion price equal to the lowest price per share at which the most senior series of Serina shares has been sold in a single transaction or a series of related transactions through which Serina raised at least $ 5,000,000 Upon the consummation of a merger between AgeX and Serina, the Serina Note would remain outstanding and become an intercompany asset of AgeX and an intercompany liability of Serina. The outstanding principal balance of the Serina Note with accrued interest may become immediately due and payable prior to the stated maturity date if an Event of Default as defined in the Serina Note occurs. In addition to this and any other remedy, both in equity and in law, upon the occurrence of an Event of Default, an interest rate of 10 250,000 The Serina Note Purchase Agreement and Serina Note each includes certain covenants that among other matters require financial reporting and impose certain restrictions, including (i) restrictions on the incurrence of additional indebtedness by Serina and its subsidiaries; (ii) requiring that Serina use note proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, and for general working capital; and (iii) prohibiting Serina from entering into any material sale or transfer transactions outside of the ordinary course of business, other than in a merger between AgeX and Serina, without the consent of AgeX. Subordination Agreement In connection with the issuance of the Serina Note, Serina, each other holder of Serina indebtedness (each a “Serina Lender”), and AgeX entered into a Subordination Agreement, dated March 15, 2023, pursuant to which each Serina Lender agreed to subordinate to AgeX’s rights of repayment with respect to the obligations owed under the Serina Note Purchase Agreement and the Serina Note (i) all Serina indebtedness owed to such Serina Lender under certain convertible notes between each Serina Lender and Serina, which aggregate principal amount of all of such convertible notes equals $ 1,450,000

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	5. Related Party Transactions As disclosed in Note 12 , Subsequent Events 36 10 2019 Loan Agreement On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence provided to AgeX a $ 2 18 4 1 7 7 160,000 2020 Loan Agreement On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence provided to AgeX an $ 8 18 8 28,500 3 3,670,663 2,146,436 8 Subsequent Events 2020 Warrants — 0.70 1.895 2022 Secured Convertible Promissory Note and Security Agreement On February 14, 2022, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “Secured Note”) pursuant to which Juvenescence agreed to provide to AgeX a $ 13,160,000 line of credit for a period of 12 8,160,000 of the line of credit and used $ 7,160,000 to refinance the outstanding principal and the loan origination fees under the 2019 Loan Agreement with Juvenescence. On February 9, 2023, AgeX and Juvenescence entered into an Amended and Restated Secured Convertible Promissory Note which amends and restates the Secured Note and added $ 2 million to the line of credit available to be borrowed by AgeX under the Secured Note subject to Juvenescence’s discretion to approve each loan draw. On May 9, 2023, AgeX and Juvenescence entered into an Allonge and Second Amendment to Amended and Restated Convertible Promissory Note (the “Second Amendment”) that increased the amount of the line of credit available to AgeX by $ 4,000,000 , subject to the terms of the Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. On June 2, 2023, AgeX and Juvenescence entered into a Third Amendment to Amended and Restated Convertible Promissory Note (the “Third Amendment’), to provide that (i) AgeX may draw on the available portion of the line of credit under the Secured Note until the earlier of the date a Qualified Offering as defined in the Secured Note is consummated by AgeX or October 31, 2023 (subject to Juvenescence’s discretion to approve each loan draw as provided in the Secured Note), (ii) AgeX will not be obligated to issue additional common stock purchase warrants to Juvenescence in connection with the receipt of loan funds made available pursuant to the Second Amendment, and (iii) the definition of Reverse Financing Condition was amended to extend to June 20, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by Reverse Bioengineering, Inc. The date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024 Subsequent Events During the six months ended June 30, 2023, AgeX borrowed $ 3,500,000 16,160,000 17,992,800 16,160,000 500,000 Subsequent Events As an arrangement fee for the Secured Note, AgeX will pay Juvenescence an origination fee in an amount equal to 4% of the amount each draw of loan funds, which will accrue as each draw is funded, and an additional 4% of all the total amount of funds drawn that will accrue following the end of the period during which funds may be drawn from the line of credit. The origination fee will become due and payable on the repayment date or in a pro rata amount with any prepayment of in whole or in part of the outstanding principal balance of the Secured Note. See Note 12, Subsequent Events, 2022 Warrants – 50 % of the number determined by dividing the amount of the applicable loan draw by the applicable Market Price. The Market Price was the last closing price per share of AgeX common stock on the NYSE American o preceding the delivery of the notice from AgeX requesting the draw of funds that triggered the obligation to issue 2022 Warrants. The exercise price of the 2022 Warrants is the applicable Market Price used to determine the number of Warrants issued. The 2022 Warrants will expire at 5:00 p.m. New York time three years after the date of issue. During the six months ended June 30, 2023, AgeX issued to Juvenescence 2022 Warrants to purchase 1,898,489 10,357,086 0.59 0.88 Conversion of Loan Amounts to Common Stock – 10,000,000 Default Provisions – if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date 250,000 Restrictive Covenants – 15 Security Agreement – $ 10 On March 13, 2023, AgeX and Juvenescence entered into a $ 10 10 10,000,000 10,000,000 Convertible Note Receivable Subsequent Events The outstanding principal balance of the $ 10 In lieu of accrued interest, AgeX will pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note. If (a) AgeX and Serina have not entered into a definitive merger agreement by August 31, 2023; (b) a merger between AgeX and Serina is terminated or either party gives notice to terminate the merger agreement; or (c) the merger is not consummated by March 13, 2024, then AgeX may, after written notice to Juvenescence, pay and satisfy in full any unpaid portion of the principal balance and accrued origination fees under the $ 10 AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $ 10,000,000 25,000,000 25,000,000 85 10 15 10 Derivatives and Hedging—Embedded Derivatives 10 15 10 Interest (income) expense, net Other (income) expense, net Juvenescence may convert the outstanding principal amount of the $ 10 Million Secured Note plus the accrued origination fee into AgeX common stock at the market price per share of AgeX common stock. Juvenescence may not convert the $ 10 Million Secured Note to AgeX common stock before the earlier of (i) a merger between AgeX and Serina, and (ii) March 13, 2024. Any conversion of the $ 10 Million Secured Note into AgeX common stock is subject to certain restrictions to comply with applicable requirements of the NYSE American where AgeX common stock is listed. See Note 12, Subsequent Events 10 The $ 10 During July 2023 the $ 10 Subsequent Events AgeX has entered into an Amended and Restated Security Agreement that amends the February 14, 2022 Security Agreement between AgeX and Juvenescence and adds the $ 10 10 Registration Rights AgeX entered into certain Registration Rights Agreements, as amended, pursuant to which AgeX has agreed to register for sale under the Securities Act of 1933, as amended (the “Securities Act”) all shares of AgeX common stock presently held by Juvenescence or that may be acquired by Juvenescence through the exercise of common stock purchase warrants that they hold or that they may acquire pursuant to the 2020 Loan Agreement and pursuant to the Secured Note, and shares that they may acquire through the conversion of those loans into AgeX common stock. AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of AgeX common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence. Debt Issuance Costs In accordance with ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of June 30, 2023 (in thousands): Schedule of Debt Issuance Costs and Debt Balances Drawdown of Funds Origination Fee Total Debt Debt Issuance Costs Amortization of Debt Issuance Costs Total Debt, Net Current 2020 Loan Agreement $ 8,000 $ - $ 8,000 $ (2,806 ) $ 2,806 $ 8,000 Secured Note 16,160 1,258 17,418 (5,909 ) 3,434 14,943 Total current, net 24,160 1,258 25,418 (8,715 ) 6,240 22,943 Non-current $ 10 10,000 384 10,384 (350 ) 34 10,068 Total debt, net $ 34,160 $ 1,642 $ 35,802 $ (9,065 ) $ 6,274 $ 33,011 Related Party Payables Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, is devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $ 280,000 230,000 141,000 Indemnification Agreements On March 13, 2023, AgeX executed that certain Letter of Indemnification in Lieu of or Supplemental to a Medallion Signature Guarantee (“Letter of Indemnification”), pursuant to which AgeX agreed to indemnify American Stock Transfer & Trust Company, LLC and its affiliates, successors and assigns (the “AST Indemnity”) from and against any and all claims, damages, liabilities or losses arising out of the transfer of all of the AgeX common stock held by Juvenescence to its wholly-owned subsidiary, Juvenescence US Corp. (the “Share Transfer”). In connection with AgeX’s execution of the Letter of Indemnification, AgeX and Juvenescence entered into that certain Transfer of Shares of AgeX Therapeutics, Inc. Common Stock – Indemnification Agreement, pursuant to which Juvenescence agreed to indemnify AgeX against any and all claims, damages, liabilities or losses arising out of the Share Transfer or AST Indemnity.

Warrant Liability

Warrant Liability	6 Months Ended
	Jun. 30, 2023
Warrant Liability
Warrant Liability	6. Warrant Liability AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock Distinguishing Liabilities from Equity, As a condition of each amount drawn up to $ 15,160,000 Related Party Transactions AgeX has utilized the full credit available under the Secured Note that is subject to warrants and accordingly the warrants were issued for each of the advances of loan funds under the Secured Note. After all relevant assessments, AgeX determined that the warrants issued under the Secured Note require classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity 15,160,000 15,160,000 Under the Third Amendment, AgeX is not obligated to issue additional warrants to Juvenescence in connection with the receipt of loan funds up to $ 4 Related Party Transactions, The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date, the date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows: Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model Black-Scholes Assumptions Exercise Price (1) Warrant Expiration Date (2) Stock Price (3) Interest Rate (annual) (4) Volatility (annual) (5) Time to Maturity (Years) Calculated Fair Value per Share Inception Date: 2/14/2022 $ 0.780 2/13/2025 $ 0.691 1.80 % 122.99 % 3 $ 0.486 Issuance Date: 2/14/2022 $ 0.780 2/13/2025 $ 0.691 1.80 % 122.99 % 3 $ 0.486 Issuance Date: 2/15/2022 $ 0.780 2/14/2025 $ 0.747 1.80 % 123.28 % 3 $ 0.535 Period Ended 3/31/2022 $ 0.940 3/30/2025 $ 0.854 2.45 % 123.28 % 3 $ 0.607 Issuance Date: 4/4/2022 $ 0.880 4/3/2025 $ 0.819 2.61 % 123.31 % 3 $ 0.585 Issuance Date: 6/6/2022 $ 0.711 6/5/2025 $ 0.800 2.94 % 122.62 % 3 $ 0.592 Period Ended 6/30/2022 $ 0.600 6/29/2025 $ 0.576 2.99 % 122.21 % 3 $ 0.413 Issuance Date: 8/16/2022 $ 0.670 8/15/2025 $ 0.640 3.19 % 121.37 % 3 $ 0.457 Period Ended 9/30/2022 $ 0.610 9/29/2025 $ 0.562 4.25 % 121.49 % 3 $ 0.401 Issuance Date: 10/21/2022 $ 0.690 10/20/2025 $ 0.620 4.52 % 120.51 % 3 $ 0.439 Issuance Date: 12/14/2022 $ 0.590 12/13/2025 $ 0.540 3.94 % 120.01 % 3 $ 0.381 Period Ended 12/31/2022 $ 0.550 12/30/2025 $ 0.552 4.22 % 119.31 % 3 $ 0.396 Issuance Date: 1/25/2023 $ 0.735 1/24/2026 $ 0.751 3.84 % 119.17 % 3 $ 0.540 Inception Date: 2/9/2023 $ 0.703 2/8/2026 $ 0.660 4.15 % 118.94 % 3 $ 0.466 Issuance Date: 2/15/2023 $ 0.624 2/14/2026 $ 0.600 4.35 % 118.93 % 3 $ 0.426 Period Ended 3/31/2023 $ 0.661 3/30/2026 $ 0.663 3.81 % 113.43 % 3 $ 0.459 Issuance Date: 4/4/2023 $ 0.661 4/3/2026 $ 0.673 3.60 % 113.01 % 3 $ 0.466 (1) Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table). For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $ 2,000,000 (2) Warrants are exercisable over a three-year period from each Issuance Date. (3) Based on the market price of AgeX’s common stock on the NYSE American as of each date presented. (4) Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve. (5) Based on the historical daily volatility of AgeX common stock as of each date presented. The warrants outstanding and fair values at each of the respective valuation dates are summarized below: Schedule of Warrant Outstanding and Fair Values Warrant Liability Credit Line and Draw Amounts (in thousands) Warrants Fair Value per Share Fair Value (in thousands) Fair value as of January 1, 2022 $ - - $ - $ - Fair value at initial measurement date of 2/14/2022 13,160 (1) 8,435,897 (2) 0.4864 4,103 Fair value of warrants issued on 2/14/2022 (7,160 ) (3) (4,589,743 ) (4) 0.4864 (2,232 ) Fair value of warrants issued on 2/15/2022 (1,000 ) (3) (641,025 ) (4) 0.5349 (343 ) Fair value of warrants issued on 4/4/2022 (1,000 ) (3) (568,440 ) (4) 0.5854 (333 ) Fair value of warrants issued on 6/6/2022 (1,000 ) (3) (703,234 ) (4) 0.5924 (417 ) Fair value of warrants issued on 8/16/2022 (1,000 ) (3) (746,380 ) (4) 0.4569 (341 ) Fair value of warrants issued on 10/21/2022 (500 ) (3) (362,318 ) (4) 0.4386 (159 ) Fair value of warrants issued on 12/14/2022 (1,000 ) (3) (847,457 ) (4) 0.3810 (323 ) Change in fair value of warrants - - - 225 Fair value as of December 31, 2022 $ 500 (1) 454,545 (2) $ 0.3960 $ 180 Fair value of warrants issued on 1/25/2023 (500 ) (3) (340,136 ) (4) 0.5395 (184 ) Fair value at initial measurement date of 2/9/2023 2,000 (1) 1,422,879 (2) 0.4657 663 Fair value of warrants issued on 2/15/2023 (1,000 ) (3) (801,924 ) (4) 0.4263 (342 ) Fair value of warrants issued on 4/4/2023 (1,000 ) (3) (756,429 ) (4) 0.4660 (352 ) Change in fair value of warrants - - - 35 Fair value as of June 30, 2023 $ - (1) - (2) $ - $ - (1) Amount of credit available under the Secured Note on date of inception and as of each period end date. For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $ 2,000,000 (2) Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date. (3) Amount of drawdown as of the date presented. (4) Number of warrants issued upon receipt of amounts drawn against the Secured Note as of the date presented. During the three and six months ended June 30, 2023, AgeX recorded a loss on change in fair value of warrants of $ 5,000 35,000 168,000 255,000 The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and AgeX’s stock prices and historical volatility as inputs. None of the warrants issued have been exercised.

Stockholders_ Deficit

Stockholders’ Deficit	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders’ Deficit	7. Stockholders’ Deficit Preferred Stock AgeX is authorized to issue up to 5,000,000 0.0001 no Subsequent Events 36 Common Stock AgeX has 200,000,000 0.0001 37,951,261 37,949,196 Issuance and Sale of Warrants by AgeX In connection with the $ 2,500,000 1,898,489 Warrant Liability Pursuant to the Third Amendment, no warrants were issued in connection with the $ 1,000,000 of additional drawdowns of loan funds after June 1, 2023. See Note 5, Related Party Transactions, At-the-Market Offering Facility On January 8, 2021, AgeX entered into a sales agreement with Chardan relating to the sale of shares of AgeX common stock, par value $ 0.0001 12.6 no

Stock-Based Awards

Stock-Based Awards	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Awards	8. Stock-Based Awards Equity Incentive Plan Awards AgeX has an Equity Incentive Plan (the “Plan”) under which a maximum of 8,500,000 A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price): Summary of Stock Option Activity Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted- Average Exercise Price Balance at December 31, 2022 5,139 3,261 3 $ 2.25 Restricted stock units vested - - (3 ) - Balance at June 30, 2023 5,139 3,261 - $ 2.25 Options exercisable at June 30, 2023 3,016 $ 2.34 There have been no Stock-based Compensation Expense AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC 718, Compensation – Stock Compensation AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under AgeX’s 2017 Equity Incentive Plan (the “Incentive Plan”). The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period. Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations. Operating expenses include stock-based compensation expense as follows (in thousands): Schedule of Stock Based Compensation Expense 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 2 $ 8 $ 7 $ 17 General and administrative 33 190 98 420 Total stock-based compensation expense $ 35 $ 198 $ 105 $ 437 The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions including expected life, risk-free interest rates, volatility, and dividend yield. The assumptions that were used to calculate the grant date fair value of employee and non-employee stock option grants for the three and six months ended June 30, 2022 were as follows: Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options Three Months Ended June 30, Six Months Ended June 30, 2023 (1) 2022 2023 (1) 2022 Grant price $ - $ 0.71 $ - $ 0.79 Market price $ - $ 0.71 $ - $ 0.79 Expected life (in years) - 6.08 - 5.58 Volatility - 128.35 % - 130.71 % Risk-free interest rates - 2.90 % - 1.74 % Dividend yield - - % - - % (1) There were no stock options granted under the Plan during the three and six months ended June 30, 2023. The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If AgeX had made different assumptions, its stock-based compensation expense and net loss for the six months ended June 30, 2023 and 2022 may have been significantly different. AgeX does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270 , Income Taxes, Interim Reporting For the three and six months ended June 30, 2023 and 2022, AgeX experienced a loss; therefore, no Due to losses incurred for all periods presented, AgeX did not record a provision or benefit for income taxes. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all of its deferred tax assets for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended
	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	10. Supplemental Cash Flow Information Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the six months ended June 30, 2023 and 2022 are as follows (in thousands): Schedule of Non-cash Investing and Financing Transactions 2023 2022 Six Months Ended June 30, 2023 2022 Cash paid during the period for interest $ 23 $ 12 Issuance of common stock upon vesting of restricted stock units (Note 8) $ 2 $ 5 Issuance of warrants for debt issuance under the 2020 Loan Agreement $ - $ 178 Fair value of liability classified warrants at debt inception date (Note 6) $ 663 $ 3,325 Debt refinanced with new debt (Note 5) $ - $ 7,160

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Office Lease Agreement AgeX leases office space in Alameda, California. For 2022 base monthly rent was $ 1,074 844 ASC 842 For the office lease, AgeX has elected to not apply the recognition requirements under ASC 842 as lease cost on a straight-line basis over the lease term because the amount of the lease payments is not deemed material. There were no future minimum lease commitments as of June 30, 2023. Litigation – General AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations. Tax Filings AgeX tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes AgeX has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the unaudited condensed consolidated interim financial statements. Employment Contracts AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations. Indemnification In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s research and development programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s research and development. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property licensed from AgeX to third parties. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. The sales agreement between AgeX and Chardan also includes indemnification provisions pursuant to which the parties have agreed to indemnify each other from certain liabilities that could arise from the offer and sale of AgeX common stock through the ATM facility, including liabilities under the Securities Act. Similarly, the Registration Rights Agreement between Juvenescence and AgeX includes indemnification provisions pursuant to which the parties will indemnify each other from certain liabilities in connection with the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. AgeX has also agreed to provide the AST Indemnity pursuant to the Letter of Indemnification described in Note 5, Related Party Transactions Notice of Delisting On April 20, 2023, AgeX received a letter (the “2023 Deficiency Letter”) from the staff of the Exchange indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $ 2,000,000 4,000,000 6,000,000 On May 17, 2023 AgeX received a notice from the staff of the Exchange indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the Exchange’s Company Guide by the end of a compliance plan period that expired on May 17, 2023. Specifically, AgeX does not meet the continued listing standards because it has stockholders equity of less than (A) $ 2,000,000 4,000,000 6,000,000 On May 24, 2023, AgeX filed a request for a review of the delisting determination by a Committee of the Board of Directors of the Exchange. On May 31, 2023, AgeX received a notice from the staff of the Exchange which scheduled a hearing for July 25, 2023. On July 24, 2023, AgeX increased its stockholders equity and remediated the deficiency by issuing shares of preferred stock to Juvenescence in exchange for the extinguishment of $ 36 Subsequent Events

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events Additional Loans Under Secured Note On July 5, 2023 and on August 1, 2023, AgeX drew $ 500,000 Amendment of Secured Note On July 31, 2023, AgeX and Juvenescence entered into a Fourth Amendment (the “Fourth Amendment”) to the Secured Note to provide that (i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bio, and (ii) Juvenescence may convert the outstanding amount of the Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion. The 19.9% Cap is a provision of the Secured Note that limits the amount of common stock that Juvenescence may acquire through the conversion of Secured Note loans in order to comply with NYSE American requirements pertaining to the amount of shares that a listed company, such as AgeX, may sell at a price less than the market prices prevailing at the time the loans were made (the “Drawdown Market Prices”) without shareholder approval. Amendment of $10 Million Secured Note On July 31, 2023, AgeX and Juvenescence also entered into an amendment to the $ 10 10 10 Debt Exchanged for Preferred Stock and Remediation of Stock Exchange Listing Deficiency On July 24, 2023, AgeX issued to Juvenescence 211,600 148,400 36 10 10 6 The NYSE American approved the listing of the 36,939,190 13,060,809 Summary of Preferred Stock The following is a summary of the principal terms of the Series A Preferred Stock and Series B Preferred Stock (collectively “Preferred Stock”). This discussion of the Preferred Stock is a summary only, does not purport to be complete, and is qualified in all respects by the full terms of the Series A Preferred Stock and Series B Preferred Stock, including the respective powers, designations, preferences, rights qualifications, limitations, and restrictions of each such series of Preferred Stock, are set forth in the respective forms of Certificate of Designation of each such series of Preferred Stock. Dividends The Preferred Stock is not entitled to receive any payment or distribution of cash or other dividends. Liquidation Preference In the event of any voluntary or involuntary liquidation, dissolution or other winding up of the affairs of AgeX, subject to the preferences and other rights of any senior stock, before any assets of AgeX shall be distributed to holders of common stock or other junior stock, all of the assets of AgeX available for distribution to stockholders shall be distributed among the holders of Series A Preferred Stock and Series B Preferred Stock and any other “parity stock” that may be issued ranking parri passu Conversion of Preferred Stock into Common Stock Each share of Preferred Stock shall be convertible into a number of shares of AgeX common stock determined by dividing (x) a number equal to the number of dollars and cents comprising the subscription price, by (y) a number equal to the number of dollars and cents comprising the conversion price. The subscription price per share of Preferred Stock is $ 100 0.72 Optional Conversion Preferred Stock shall be convertible into common stock at the election of the holder of shares of Preferred Stock at any time and from time to time. Automatic Conversion The outstanding shares of Series A Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders (“Automatic Conversion”) upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina, or a subsidiary thereof; and (y) February 1, 2024. Further, if the holders of at least a majority of the outstanding shares of Series A Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, then the outstanding shares of Series A Preferred Stock shall be converted into common stock upon such approval or consent. The outstanding shares of Series B Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina or a subsidiary thereof; and (y) February 1, 2024, provided that such conversion is not limited by the 19.9% Cap or the 50% Cap as described below; and if Automatic Conversion would then be limited by the 19.9% Cap or the 50% Cap, the Automatic Conversion shall take place on the tenth day after such stockholder approvals have been obtained as may be required to permit such Automatic Conversion without the limitations of the 19.9% Cap and the 50% Cap. Further, if the holders of at least a majority of the outstanding shares of Series B Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, and the conversion is not then limited by the 19.9% Cap or the 50% Cap, then the outstanding shares of Series B Preferred Stock shall be converted into common stock upon such approval or consent. Certain Limitations on Conversion of Series B Preferred Stock If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the “19.9% Cap” upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued upon conversion of all shares of Series B Preferred Stock shall be an amount equal to the 19.9% Cap. The 19.9% Cap means 7,550,302 shares of common stock, which is 19.9% of the shares of common stock outstanding on February 14, 2022 when the Secured Note, a portion of which has not been approved by AgeX stockholders for conversion into common stock without regard to the 19.9% Cap and 50% Cap, was issued. If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the 50% Cap upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued to a holder of Series B Preferred Stock upon conversion of such shares shall be an amount that, when added to other shares of common stock owned by such holder immediately prior to such conversion would equal one share less than the 50% Cap. Adjustment of conversion price and subscription price If AgeX shall (a) declare a dividend or make a distribution on its common stock in shares of common stock, (b) subdivide or reclassify the outstanding common stock into a greater number of shares, or (c) combine or reclassify the outstanding common stock into a smaller number of shares, the conversion price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. If AgeX shall (i) declare a dividend or make a distribution on a series of Preferred Stock in shares of Preferred Stock, (ii) subdivide or reclassify the outstanding shares of a series of Preferred Stock into a greater number of shares, or (iii) combine or reclassify the outstanding shares of a series of Preferred Stock into a smaller number of shares, the subscription price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. Successive adjustments in the conversion price or subscription price, as applicable, shall be made whenever any event specified above shall occur. No Fractional Shares No fractional share of common stock or scrip shall be issued upon conversion of Preferred Stock. Instead of any fractional share of common stock which would otherwise be issuable upon conversion of any Preferred Stock, AgeX will pay a cash adjustment in respect of such fractional interest in an amount equal to that fractional interest at the then fair value determined in accordance with the terms of the Preferred Stock. Voting Rights The following matters shall require the approval of the holders of a majority of the shares of a series of Preferred Stock then outstanding, voting as a separate class: (i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock. Governing Law The powers, designations, preferences, rights, qualifications, limitations, and restrictions of either series of Preferred Stock, the validity, authorization and issuance of such Preferred Stock, and the conversion of such Preferred Stock into common stock shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof, and all legal proceedings pursuant or with respect to or concerning such matters (a “Proceeding”), whether brought by or against a holder of Preferred Stock or AgeX or any of their respective directors, officers, stockholders, employees or agents, shall be commenced in the state and federal courts sitting in the State of Delaware (the “Delaware Courts”). The Preferred Stock provides that (a) AgeX and each holder of Preferred Stock irrevocably submits to the exclusive jurisdiction of the Delaware Courts for the adjudication of any Proceeding, and irrevocably waives, and agrees not to assert in any Proceeding any claim that they are not personally subject to the jurisdiction of such Delaware Courts, or such Delaware Courts are an improper or inconvenient venue for such Proceeding, and (b) AgeX and each holder of Preferred Stock irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to such party and agrees that such service shall constitute good and sufficient service of process and notice Registration Rights Agreement AgeX and Juvenescence have entered into a Registration Rights Agreement pursuant to which AgeX has agreed to use commercially reasonable efforts to register the for sale under the Securities Act the shares of common stock issuable upon conversion of Preferred Stock. A registration statement must be filed upon request of Juvenescence if Form S-3 is available to AgeX. Juvenescence will also have “piggy-back” registration rights if AgeX files a registration statement for the sale of shares for itself or other stockholders, subject to certain customary exceptions based on the nature of the registration statement. AgeX will bear the expenses of the registration statement but not underwriting or broker’s commissions related to the sale of the common stock. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. Research Grant Award On August 11, 2023, AgeX received a Notice of Award from the National Institutes of Health (NIH, National Heart, Lung, and Blood Institute) for a grant of approximately $ 341,000

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The consolidated financial statements include the accounts of AgeX and its subsidiaries in which AgeX has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which AgeX is the primary beneficiary (as described in more detail below). For consolidated entities where AgeX has less than 100 AgeX assesses whether it is the primary beneficiary of a variable interest entity (“VIE”) at the inception of the arrangement and at each reporting date. This assessment is based on its power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and AgeX’s obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. If the entity is within the scope of the variable interest model and meets the definition of a VIE, AgeX considers whether it must consolidate the VIE or provide additional disclosures regarding its involvement with the VIE. If AgeX determines that it is the primary beneficiary of the VIE, AgeX will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event. For entities AgeX holds as an equity investment that are not consolidated under the VIE model, AgeX will consider whether its investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model. AgeX has three subsidiaries, Reverse Bio, ReCyte Therapeutics, Inc. (“ReCyte”), and NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”). Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTR TM TM 94.8 50 Consolidation
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of AgeX’s embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. The financial information for private companies may not be available and, even if available, that information may be limited and/or unreliable. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected. See Note 6, Warrant Liability
Concentration of credit risk and other risks and uncertainties	Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject AgeX to concentrations of risk consist principally of cash equivalents and a convertible note receivable. AgeX maintains its cash deposits in Federal Deposit Insurance Corporation insured financial institutions within the federally insured limits. Even if balances were to exceed the federally insured limits, AgeX does not believe that it would be exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. AgeX also monitors the creditworthiness of the borrower of the convertible promissory note. AgeX believes that any concentration of credit risk in a convertible note receivable was mitigated in part by (i) AgeX’s right to convert loan amounts owed to AgeX into shares of equity securities of the borrower in the event the borrower completes a financing in at least a designated amount, and (ii) AgeX’s right to tender the convertible note receivable to a lender to settle a convertible note payable. See Notes 4, Convertible Note Receivable Related Party Transactions Product candidates developed by AgeX and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by AgeX or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on AgeX.
Fair value measurements of financial instruments	Fair value measurements of financial instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date. The carrying values of cash equivalents, accounts receivable and accounts payable, are carried at, or approximate, fair value as of the reporting date because of their short-term nature. The convertible note receivable is reported at fair value as it bears market rates of interest. Fair values for the AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, Fair Value Measurements and Disclosures ● Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 – Inputs to the valuation methodology include observable quoted prices (other than quoted market prices included within Level 1) for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments. ● Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value. In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items. The discounted conversion prices triggered by certain qualified events in the Serina Note and the $ 10 Convertible Note Receivable Related Party Transactions Subsequent Events The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times. The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations are discussed further in Note 6, Warrant Liability See Note 6, Warrant Liability
Cash, cash equivalents, and restricted cash	Cash, cash equivalents, and restricted cash In accordance with Accounting Standards Update (“ASU”) 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash Schedule of Cash, Cash Equivalents and Restricted Cash June 30, 2023 (unaudited) December 31, 2022 Cash and cash equivalents $ 261 $ 645 Restricted cash (1) 50 50 Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows $ 311 $ 695 (1) Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.
Long-lived intangible assets, net	Long-lived intangible assets, net Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&D”) and patents is stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 10 Selected Balance Sheet Components
Impairment of long-lived assets	Impairment of long-lived assets AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consists entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of June 30, 2023, there has been no impairment of long-lived assets.
Leases	Leases AgeX accounts for leases in accordance with ASU 2016-02, Leases Codification Improvements to Topic 842, Leases, Leases (Topic 842): Targeted Improvements, (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less. AgeX leases office space in Alameda, California. For 2022 base monthly rent was $ 1,074 844
Accounting for warrants	Accounting for warrants AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock Related Party Transactions Warrant Liability
Revenue recognition	Revenue recognition AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. ESI BIO Research Products – Arrangements with multiple performance obligations –
Research and development	Research and development Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and contractors, sponsored research agreements with certain universities, and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations.
General and administrative	General and administrative General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees.
Basic and diluted net loss per share attributable to common stockholders	Basic and diluted net loss per share attributable to common stockholders Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any. For the three and six months ended June 30, 2023 and 2022, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive. The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Stock options 3,261 3,274 3,261 3,333 Warrants (1) 13,246 9,794 13,013 8,099 Restricted stock units - 12 1 13 (1) As of June 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase 12,503,522 10,323,105 Related Party Transactions
Reclassifications	Reclassifications Certain reclassifications have been made to the prior period’s condensed consolidated interim financial statements to conform to current year presentation. Additionally, certain financial information is presented on a rounded basis, which may cause minor differences.
Recently adopted accounting pronouncements	Recently adopted accounting pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In March 2022, the FASB issued ASU No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures On July 14, 2023, the FASB issued ASU No. 2023-02, P resentation of Financial Statements (Topic 205), Income Statement – Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Cash, Cash Equivalents and Restricted Cash	Schedule of Cash, Cash Equivalents and Restricted Cash June 30, 2023 (unaudited) December 31, 2022 Cash and cash equivalents $ 261 $ 645 Restricted cash (1) 50 50 Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows $ 311 $ 695 (1) Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Stock options 3,261 3,274 3,261 3,333 Warrants (1) 13,246 9,794 13,013 8,099 Restricted stock units - 12 1 13 (1) As of June 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase 12,503,522 10,323,105 Related Party Transactions

Selected Balance Sheet Compon_2

Selected Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Intangible Assets, Net	At June 30, 2023 and December 31, 2022, intangible assets, primarily consisting of acquired IPR&D and patents, and accumulated amortization were as follows (in thousands): Schedule of Intangible Assets, Net June 30, 2023 (unaudited) December 31, 2022 Intangible assets $ 1,312 $ 1,312 Accumulated amortization (639 ) (574 ) Total intangible assets, net $ 673 $ 738
Schedule of Amortization Assets	Amortization of intangible assets for periods subsequent to June 30, 2023 is as follows (in thousands): Schedule of Amortization Assets Year Ending December 31, Amortization Expense 2023 $ 66 2024 131 2025 131 2026 132 Thereafter 213 Total $ 673
Schedule of Accounts Payable and Accrued Liabilities	At June 30, 2023 and December 31, 2022, accounts payable and accrued liabilities were comprised of the following (in thousands): Schedule of Accounts Payable and Accrued Liabilities June 30, 2023 (unaudited) December 31, 2022 Accounts payable $ 506 $ 568 Accrued compensation 199 193 Accrued vendors and other expenses 256 273 Total accounts payable and accrued liabilities $ 961 $ 1,034

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Schedule of Debt Issuance Costs and Debt Balances	The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of June 30, 2023 (in thousands): Schedule of Debt Issuance Costs and Debt Balances Drawdown of Funds Origination Fee Total Debt Debt Issuance Costs Amortization of Debt Issuance Costs Total Debt, Net Current 2020 Loan Agreement $ 8,000 $ - $ 8,000 $ (2,806 ) $ 2,806 $ 8,000 Secured Note 16,160 1,258 17,418 (5,909 ) 3,434 14,943 Total current, net 24,160 1,258 25,418 (8,715 ) 6,240 22,943 Non-current $ 10 10,000 384 10,384 (350 ) 34 10,068 Total debt, net $ 34,160 $ 1,642 $ 35,802 $ (9,065 ) $ 6,274 $ 33,011

Warrant Liability (Tables)

Warrant Liability (Tables)	6 Months Ended
	Jun. 30, 2023
Warrant Liability
Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model	The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date, the date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows: Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model Black-Scholes Assumptions Exercise Price (1) Warrant Expiration Date (2) Stock Price (3) Interest Rate (annual) (4) Volatility (annual) (5) Time to Maturity (Years) Calculated Fair Value per Share Inception Date: 2/14/2022 $ 0.780 2/13/2025 $ 0.691 1.80 % 122.99 % 3 $ 0.486 Issuance Date: 2/14/2022 $ 0.780 2/13/2025 $ 0.691 1.80 % 122.99 % 3 $ 0.486 Issuance Date: 2/15/2022 $ 0.780 2/14/2025 $ 0.747 1.80 % 123.28 % 3 $ 0.535 Period Ended 3/31/2022 $ 0.940 3/30/2025 $ 0.854 2.45 % 123.28 % 3 $ 0.607 Issuance Date: 4/4/2022 $ 0.880 4/3/2025 $ 0.819 2.61 % 123.31 % 3 $ 0.585 Issuance Date: 6/6/2022 $ 0.711 6/5/2025 $ 0.800 2.94 % 122.62 % 3 $ 0.592 Period Ended 6/30/2022 $ 0.600 6/29/2025 $ 0.576 2.99 % 122.21 % 3 $ 0.413 Issuance Date: 8/16/2022 $ 0.670 8/15/2025 $ 0.640 3.19 % 121.37 % 3 $ 0.457 Period Ended 9/30/2022 $ 0.610 9/29/2025 $ 0.562 4.25 % 121.49 % 3 $ 0.401 Issuance Date: 10/21/2022 $ 0.690 10/20/2025 $ 0.620 4.52 % 120.51 % 3 $ 0.439 Issuance Date: 12/14/2022 $ 0.590 12/13/2025 $ 0.540 3.94 % 120.01 % 3 $ 0.381 Period Ended 12/31/2022 $ 0.550 12/30/2025 $ 0.552 4.22 % 119.31 % 3 $ 0.396 Issuance Date: 1/25/2023 $ 0.735 1/24/2026 $ 0.751 3.84 % 119.17 % 3 $ 0.540 Inception Date: 2/9/2023 $ 0.703 2/8/2026 $ 0.660 4.15 % 118.94 % 3 $ 0.466 Issuance Date: 2/15/2023 $ 0.624 2/14/2026 $ 0.600 4.35 % 118.93 % 3 $ 0.426 Period Ended 3/31/2023 $ 0.661 3/30/2026 $ 0.663 3.81 % 113.43 % 3 $ 0.459 Issuance Date: 4/4/2023 $ 0.661 4/3/2026 $ 0.673 3.60 % 113.01 % 3 $ 0.466 (1) Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table). For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $ 2,000,000 (2) Warrants are exercisable over a three-year period from each Issuance Date. (3) Based on the market price of AgeX’s common stock on the NYSE American as of each date presented. (4) Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve. (5) Based on the historical daily volatility of AgeX common stock as of each date presented.
Schedule of Warrant Outstanding and Fair Values	The warrants outstanding and fair values at each of the respective valuation dates are summarized below: Schedule of Warrant Outstanding and Fair Values Warrant Liability Credit Line and Draw Amounts (in thousands) Warrants Fair Value per Share Fair Value (in thousands) Fair value as of January 1, 2022 $ - - $ - $ - Fair value at initial measurement date of 2/14/2022 13,160 (1) 8,435,897 (2) 0.4864 4,103 Fair value of warrants issued on 2/14/2022 (7,160 ) (3) (4,589,743 ) (4) 0.4864 (2,232 ) Fair value of warrants issued on 2/15/2022 (1,000 ) (3) (641,025 ) (4) 0.5349 (343 ) Fair value of warrants issued on 4/4/2022 (1,000 ) (3) (568,440 ) (4) 0.5854 (333 ) Fair value of warrants issued on 6/6/2022 (1,000 ) (3) (703,234 ) (4) 0.5924 (417 ) Fair value of warrants issued on 8/16/2022 (1,000 ) (3) (746,380 ) (4) 0.4569 (341 ) Fair value of warrants issued on 10/21/2022 (500 ) (3) (362,318 ) (4) 0.4386 (159 ) Fair value of warrants issued on 12/14/2022 (1,000 ) (3) (847,457 ) (4) 0.3810 (323 ) Change in fair value of warrants - - - 225 Fair value as of December 31, 2022 $ 500 (1) 454,545 (2) $ 0.3960 $ 180 Fair value of warrants issued on 1/25/2023 (500 ) (3) (340,136 ) (4) 0.5395 (184 ) Fair value at initial measurement date of 2/9/2023 2,000 (1) 1,422,879 (2) 0.4657 663 Fair value of warrants issued on 2/15/2023 (1,000 ) (3) (801,924 ) (4) 0.4263 (342 ) Fair value of warrants issued on 4/4/2023 (1,000 ) (3) (756,429 ) (4) 0.4660 (352 ) Change in fair value of warrants - - - 35 Fair value as of June 30, 2023 $ - (1) - (2) $ - $ - (1) Amount of credit available under the Secured Note on date of inception and as of each period end date. For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $ 2,000,000 (2) Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date. (3) Amount of drawdown as of the date presented. (4) Number of warrants issued upon receipt of amounts drawn against the Secured Note as of the date presented.

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price): Summary of Stock Option Activity Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted- Average Exercise Price Balance at December 31, 2022 5,139 3,261 3 $ 2.25 Restricted stock units vested - - (3 ) - Balance at June 30, 2023 5,139 3,261 - $ 2.25 Options exercisable at June 30, 2023 3,016 $ 2.34
Schedule of Stock Based Compensation Expense	Operating expenses include stock-based compensation expense as follows (in thousands): Schedule of Stock Based Compensation Expense 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 2 $ 8 $ 7 $ 17 General and administrative 33 190 98 420 Total stock-based compensation expense $ 35 $ 198 $ 105 $ 437
Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options	Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options Three Months Ended June 30, Six Months Ended June 30, 2023 (1) 2022 2023 (1) 2022 Grant price $ - $ 0.71 $ - $ 0.79 Market price $ - $ 0.71 $ - $ 0.79 Expected life (in years) - 6.08 - 5.58 Volatility - 128.35 % - 130.71 % Risk-free interest rates - 2.90 % - 1.74 % Dividend yield - - % - - % (1) There were no stock options granted under the Plan during the three and six months ended June 30, 2023.

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Non-cash Investing and Financing Transactions	Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the six months ended June 30, 2023 and 2022 are as follows (in thousands): Schedule of Non-cash Investing and Financing Transactions 2023 2022 Six Months Ended June 30, 2023 2022 Cash paid during the period for interest $ 23 $ 12 Issuance of common stock upon vesting of restricted stock units (Note 8) $ 2 $ 5 Issuance of warrants for debt issuance under the 2020 Loan Agreement $ - $ 178 Fair value of liability classified warrants at debt inception date (Note 6) $ 663 $ 3,325 Debt refinanced with new debt (Note 5) $ - $ 7,160

Organization, Business Overvi_2

Organization, Business Overview and Liquidity (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Secured debt		$ 10,000,000
Accumulated deficit		122,156,000	$ 116,210,000
cash and cash equivalents		300,000
Juvenescence [Member] | Loan Facility Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Line of credit facility maximum borrowing capacity		$ 4,000,000
Convertible Promissory Note [Member] | Juvenescence Limited [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Secured debt	$ 10,000,000
Proceeds from convertible debt	$ 10,000,000

Schedule of Cash, Cash Equivale

Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash and cash equivalents		$ 261	$ 645
Restricted cash	[1]	50	50
Cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows		$ 311	$ 695
[1]Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		3,261	3,274	3,261	3,333
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]	13,246	9,794	13,013	8,099
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities			12	1	13
[1]As of June 30, 2023 and 2022, AgeX had issued Juvenescence warrants to purchase 12,503,522 10,323,105 Related Party Transactions

Schedule of Antidilutive Secu_2

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) (Parenthetical) - shares	Jun. 30, 2023	Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant to purchase shares of common stock	10,357,086
Loan Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant to purchase shares of common stock	12,503,522,000	10,323,105,000

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Secured debt	$ 10,000,000
Finite lived intangible asset useful life	10 years
Lessee operating lease description	(i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.
Fair Value, Inputs, Level 3 [Member]
Secured debt	$ 10,000,000
Lease Agreement [Member]
Base rent	$ 844	$ 1,074
ReCyte Therapeutics, Inc. [Member]
Ownership, percentage	100%
ReCyte Therapeutics, Inc. [Member] | Merger Agreement [Member]
Ownership, percentage	50%
Merger Agreement [Member]
Ownership, percentage	94.80%

Schedule of Intangible Assets,

Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Intangible assets	$ 1,312	$ 1,312
Accumulated amortization	(639)	(574)
Total intangible assets, net	$ 673	$ 738

Schedule of Amortization Assets

Schedule of Amortization Assets (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2023	$ 66
2024	131
2025	131
2026	132
Thereafter	213
Total	$ 673

Schedule of Accounts Payable an

Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts payable	$ 506	$ 568
Accrued compensation	199	193
Accrued vendors and other expenses	256	273
Total accounts payable and accrued liabilities	$ 961	$ 1,034

Selected Balance Sheet Compon_3

Selected Balance Sheet Components (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Amortization expense of intangible assets	$ 32	$ 33	$ 65	$ 66

Convertible Note Receivable (De

Convertible Note Receivable (Details Narrative) - USD ($)	Mar. 15, 2023	Jun. 30, 2023	Mar. 13, 2023
Short-Term Debt [Line Items]
Principal amount	$ 105,000,000
Debt interest rate	10%
Other assets	$ 250,000
Secured Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount	$ 25,000,000
Stockholder outstanding percentage	80%
Debt interest rate	20%
Subordination Agreement [Member] | Secured Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount	$ 1,450,000
Juvenescence [Member] | Secured Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount		$ 10,000,000	$ 10,000,000
Juvenescence [Member] | Convertible Note Purchase Agreement [Member]
Short-Term Debt [Line Items]
Principal amount	$ 10,000,000
Stockholder outstanding percentage	7%
Juvenescence Limited [Member] | Secured Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount	$ 5,000,000

Schedule of Debt Issuance Costs

Schedule of Debt Issuance Costs and Debt Balances (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Debt [Member]
Short-Term Debt [Line Items]
Long-Term Line of Credit	$ 24,160
Debt Instrument, Fee Amount	1,258
Long-Term Debt, Gross	25,418
Debt Issuance Cost, Gross, Noncurrent	(8,715)
Accumulated Amortization, Debt Issuance Costs, Noncurrent	6,240
Long-Term Debt	22,943
Total Debt Net [Member]
Short-Term Debt [Line Items]
Long-Term Line of Credit	34,160
Debt Instrument, Fee Amount	1,642
Long-Term Debt, Gross	35,802
Debt Issuance Cost, Gross, Noncurrent	(9,065)
Accumulated Amortization, Debt Issuance Costs, Noncurrent	6,274
Long-Term Debt	33,011
2020 Loan Agreement [Member]
Short-Term Debt [Line Items]
Long-Term Line of Credit	8,000
Debt Instrument, Fee Amount
Long-Term Debt, Gross	8,000
Debt Issuance Cost, Gross, Noncurrent	(2,806)
Accumulated Amortization, Debt Issuance Costs, Noncurrent	2,806
Long-Term Debt	8,000
Secured Note [Member]
Short-Term Debt [Line Items]
Long-Term Line of Credit	16,160
Debt Instrument, Fee Amount	1,258
Long-Term Debt, Gross	17,418
Debt Issuance Cost, Gross, Noncurrent	(5,909)
Accumulated Amortization, Debt Issuance Costs, Noncurrent	3,434
Long-Term Debt	14,943
10 Million Secured Note [Member]
Short-Term Debt [Line Items]
Long-Term Line of Credit	10,000
Debt Instrument, Fee Amount	384
Long-Term Debt, Gross	10,384
Debt Issuance Cost, Gross, Noncurrent	(350)
Accumulated Amortization, Debt Issuance Costs, Noncurrent	34
Long-Term Debt	$ 10,068

Schedule of Debt Issuance Cos_2

Schedule of Debt Issuance Costs and Debt Balances (Details) (Parenthetical) $ in Millions	Jun. 30, 2023 USD ($)
Related Party Transactions [Abstract]
Secured note	$ 10

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

6 Months Ended

Aug. 01, 2023

Jul. 31, 2023

Jul. 24, 2023

Jul. 05, 2023

May 09, 2023

Mar. 13, 2023

Feb. 13, 2023

Feb. 09, 2023

Feb. 14, 2022

Nov. 08, 2021

Feb. 10, 2021

Mar. 30, 2020

Aug. 13, 2019

Jun. 30, 2023

Mar. 15, 2023

Dec. 31, 2022

Dec. 31, 2021

Secured debt

$ 10,000,000

Warrant purchase

10,357,086

Warrants outstanding

[1]

454,545

[1]

Line of credit facility, expiration date

Feb. 14, 2024

Proceeds from sale of common stock

$ 25,000,000

Common stock held

$ 250,000

Convertiable promissoty note

$ 105,000,000

Common stock outstanding percentage

85%

2022 Warrants [Member]

Warrants issued percentage

50%

Line of Credit [Member]

Secured debt

$ 16,160,000

Secured Convertible Promissory Note [Member]

Increase in line of credit

$ 4,000,000

$ 2,000,000

$ 3,500,000

Convertiable promissoty note

25,000,000

Origination Fee [Member]

Proceeds from sale of common stock

$ 10,000,000

2022 Warrants [Member]

Warrants exercise price, minimum

$ 0.59

Warrants exercise price, maximum

$ 0.88

Common Stock [Member]

Proceeds from sale of common stock

$ 10,000,000

2020 Loan Agreement [Member]

Line of credit, term

18 months

Line of credit facility, current borrowing capacity

$ 8,000,000

$ 8,000,000

Common stock, shares

28,500

Line of credit, current borrowing capacity

$ 3,000,000

Warrant purchase

3,670,663

Warrants outstanding

2,146,436

2020 Loan Agreement [Member] | 2020 Warrants [Member]

Warrants exercise price, minimum

$ 0.70

Warrants exercise price, maximum

$ 1.895

2022 Secured Convertible Promissory Note and Security Agreement [Member]

Line of credit facility

$ 8,160,000

Line of credit, term

12 years

Line of credit facility, current borrowing capacity

$ 7,160,000

Line of credit

13,160,000

Security Agreement [Member]

Line of credit facility, description

if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date

Registration Rights Agreements [Member]

Line of credit facility, description

AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of AgeX common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence.

Subsequent Event [Member]

Secured debt

$ 10,000,000

Subsequent Event [Member] | Line of Credit [Member]

Secured debt

$ 17,992,800

Increase in line of credit

500,000

Subsequent Event [Member] | Secured Convertible Promissory Note [Member]

Increase in line of credit

$ 500,000

$ 500,000

Subsequent Event [Member] | 2020 Loan Agreement [Member]

Extinguishment of debt

8

Juvenescence Limited [Member]

Proceeds from sale of common stock

$ 10,000,000

Common stock outstanding percentage

15%

Juvenescence Limited [Member] | Minimum [Member]

Proceeds from sale of common stock

$ 10,000,000

Juvenescence Limited [Member] | Maximum [Member]

Proceeds from sale of common stock

25,000,000

Juvenescence Limited [Member] | Secured Convertible Promissory Note [Member]

Line of credit, current borrowing capacity

10,000,000

Convertiable promissoty note

$ 5,000,000

Proceeds from issuance of long term debt

10,000,000

Juvenescence Limited [Member] | Origination Fee [Member]

Proceeds from sale of common stock

10,000,000

$ 10,000,000

Juvenescence Limited [Member] | Subsequent Event [Member]

Extinguishment of debt

36

Secured debt

10,000,000

Juvenescence Limited [Member] | Subsequent Event [Member] | Origination Fee [Member]

Secured debt

10,000,000

Juvenescence Limited [Member] | Subsequent Event [Member] | 2020 Loan Agreement [Member]

Secured debt

$ 10,000,000

Juvenescence [Member]

Line of credit facility

$ 2,500,000

Warrant purchase

1,898,489

Reimbursement

$ 280,000

Accounts payable

230,000,000

$ 141,000,000

Juvenescence [Member] | Secured Convertible Promissory Note [Member]

Convertiable promissoty note

$ 10,000,000

10,000,000

Origination fee description

In lieu of accrued interest, AgeX will pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the $10 Million Secured Note into shares of AgeX common stock, (ii) repayment of the $10 Million Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the $10 Million Secured Note following an Event of Default as defined in the $10 Million Secured Note.

Juvenescence [Member] | 2019 Loan Agreement [Member]

Line of credit facility

$ 2,000,000

Line of credit, term

18 months

Increase in line of credit

$ 1,000,000

$ 4,000,000

Line of credit facility, current borrowing capacity

7,000,000

$ 7,000,000

Origination fee

$ 160,000

Juvenescence [Member] | Subsequent Event [Member]

Secured debt

$ 10,000,000

Reverse Ratio [Member]

Indebtedness

$ 15,000,000

[1]Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date.

Schedule of Warrants Liabilitie

Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) - $ / shares																	2 Months Ended	3 Months Ended			6 Months Ended
		Apr. 04, 2023	Mar. 31, 2023	Feb. 15, 2023	Feb. 09, 2023	Jan. 25, 2023	Dec. 31, 2022	Dec. 14, 2022	Oct. 21, 2022	Sep. 30, 2022	Aug. 16, 2022	Jun. 30, 2022	Jun. 06, 2022	Apr. 04, 2022	Feb. 15, 2022	Feb. 14, 2022	Mar. 31, 2022	Jun. 30, 2023	[1]	Jun. 30, 2022	Jun. 30, 2023	[1]	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Interest Rate (annual)																				2.90%			1.74%
Volatility (annual)																				128.35%			130.71%
Time to Maturity (Years)																				6 years 29 days			5 years 6 months 29 days
Inception Date [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	[2]				$ 0.703											$ 0.780
Warrant Expiration Date	[3]				Feb. 08, 2026											Feb. 13, 2025
Stock Price	[4]				$ 0.660											$ 0.691
Interest Rate (annual)	[5]				4.15%											1.80%
Volatility (annual)	[6]				118.94%											122.99%
Time to Maturity (Years)					3 years											3 years
Calculated fair value per share					$ 0.466											$ 0.486
Issuance Date [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	[2]	$ 0.661		$ 0.624		$ 0.735		$ 0.590			$ 0.670		$ 0.711	$ 0.880	$ 0.780	$ 0.780
Warrant Expiration Date	[3]	Apr. 03, 2026		Feb. 14, 2026		Jan. 24, 2026		Dec. 13, 2025			Aug. 15, 2025		Jun. 05, 2025	Apr. 03, 2025	Feb. 14, 2025	Feb. 13, 2025
Stock Price	[4]	$ 0.673		$ 0.600		$ 0.751		$ 0.540			$ 0.640		$ 0.800	$ 0.819	$ 0.747	$ 0.691
Interest Rate (annual)	[5]	3.60%		4.35%		3.84%		3.94%			3.19%		2.94%	2.61%	1.80%	1.80%
Volatility (annual)	[6]	113.01%		118.93%		119.17%		120.01%			121.37%		122.62%	123.31%	123.28%	122.99%
Time to Maturity (Years)		3 years		3 years		3 years		3 years			3 years		3 years	3 years	3 years	3 years
Calculated fair value per share		$ 0.466		$ 0.426		$ 0.540		$ 0.381			$ 0.457		$ 0.592	$ 0.585	$ 0.535	$ 0.486
Period Ending [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	[2]		$ 0.661				$ 0.550		$ 0.690	$ 0.610		$ 0.600					$ 0.940			$ 0.600			$ 0.600
Warrant Expiration Date	[3]		Mar. 30, 2026				Dec. 30, 2025		Oct. 20, 2025	Sep. 29, 2025		Jun. 29, 2025					Mar. 30, 2025
Stock Price	[4]		$ 0.663				$ 0.552		$ 0.620	$ 0.562		$ 0.576					$ 0.854			0.576			0.576
Interest Rate (annual)	[5]		3.81%				4.22%		4.52%	4.25%		2.99%					2.45%
Volatility (annual)	[6]		113.43%				119.31%		120.51%	121.49%		122.21%					123.28%
Time to Maturity (Years)			3 years				3 years		3 years	3 years		3 years					3 years
Calculated fair value per share			$ 0.459				$ 0.396		$ 0.439	$ 0.401		$ 0.413					$ 0.607			$ 0.413			$ 0.413
[1]There were no stock options granted under the Plan during the three and six months ended June 30, 2023.[2]Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table). For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $ 2,000,000

Schedule of Warrants Liabilit_2

Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model (Details) (Parenthetical) $ in Thousands	Jun. 30, 2023 USD ($)
Warrant Liability
Lines of credit current	$ 2,000,000

Schedule of Warrant Outstanding

Schedule of Warrant Outstanding and Fair Values (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended			12 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023		Jun. 30, 2022	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance				$ 500	[1]
Fair value as of period beginning balance, shares				454,545	[2]
Fair value as of period beginning balance, fair value per share				$ 0.3960
Fair value as of period beginning balance, fair value				$ 180
Fair value as of period beginning balance		$ 5	$ 168	35		$ 255
Fair value as of period beginning balance	[2]
Fair value as of period beginning balance, shares	[3]
Fair value as of period beginning balance, fair value per share
Fair value as of period beginning balance, fair value				$ 35			$ 225
Fair value as of period beginning balance	[1]						$ 500
Fair value as of period beginning balance, shares	[2]						454,545
Fair value as of period beginning balance, fair value per share							$ 0.3960
Fair value as of period beginning balance, fair value							$ 180
Initial measurement date of 2/14/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[1]						$ 13,160
Fair value as of period beginning balance, shares	[2]						8,435,897
Fair value as of period beginning balance, fair value per share							$ 0.4864
Fair value as of period beginning balance, fair value							$ 4,103
2/14/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[4]						$ (7,160)
Fair value as of period beginning balance, shares	[3]						(4,589,743)
Fair value as of period beginning balance, fair value per share							$ 0.4864
Fair value as of period beginning balance, fair value							$ (2,232)
2/15/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[4]						$ (1,000)
Fair value as of period beginning balance, shares	[3]						(641,025)
Fair value as of period beginning balance, fair value per share							$ 0.5349
Fair value as of period beginning balance, fair value							$ (343)
4/4/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[4]						$ (1,000)
Fair value as of period beginning balance, shares	[3]						(568,440)
Fair value as of period beginning balance, fair value per share							$ 0.5854
Fair value as of period beginning balance, fair value							$ (333)
6/6/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[4]						$ (1,000)
Fair value as of period beginning balance, shares	[3]						(703,234)
Fair value as of period beginning balance, fair value per share							$ 0.5924
Fair value as of period beginning balance, fair value							$ (417)
8/16/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[4]						$ (1,000)
Fair value as of period beginning balance, shares	[3]						(746,380)
Fair value as of period beginning balance, fair value per share							$ 0.4569
Fair value as of period beginning balance, fair value							$ (341)
10/21/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[4]						$ (500)
Fair value as of period beginning balance, shares	[3]						(362,318)
Fair value as of period beginning balance, fair value per share							$ 0.4386
Fair value as of period beginning balance, fair value							$ (159)
12/14/2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[4]						$ (1,000)
Fair value as of period beginning balance, shares	[3]						(847,457)
Fair value as of period beginning balance, fair value per share							$ 0.3810
Fair value as of period beginning balance, fair value							$ (323)
1/25/2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[4]			$ (500)
Fair value as of period beginning balance, shares	[3]			(340,136)
Fair value as of period beginning balance, fair value per share				$ 0.5395
Fair value as of period beginning balance, fair value				$ (184)
2/9/2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[1]			$ 2,000
Fair value as of period beginning balance, shares	[2]			1,422,879
Fair value as of period beginning balance, fair value per share				$ 0.4657
Fair value as of period beginning balance, fair value				$ 663
2/15/2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[4]			$ (1,000)
Fair value as of period beginning balance, shares	[3]			(801,924)
Fair value as of period beginning balance, fair value per share				$ 0.4263
Fair value as of period beginning balance, fair value				$ (342)
4/4/2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value as of period beginning balance	[4]			$ (1,000)
Fair value as of period beginning balance, shares	[3]			(756,429)
Fair value as of period beginning balance, fair value per share				$ 0.4660
Fair value as of period beginning balance, fair value				$ (352)
[1]Amount of credit available under the Secured Note on date of inception and as of each period end date. For this purpose, the date on which the Secured Note was amended and restated to increase the line of credit by $ 2,000,000

Schedule of Warrant Outstandi_2

Schedule of Warrant Outstanding and Fair Values (Details) (Parenthetical) $ in Thousands	Jun. 30, 2023 USD ($)
Warrant Liability
Lines of credit current	$ 2,000,000

Warrant Liability (Details Narr

Warrant Liability (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Secured debt	$ 10,000,000		$ 10,000,000
Fair value of warrant liability	5,000	$ 168,000	35,000	$ 255,000
Juvenescence [Member]
Loan funds	4,000,000		4,000,000
Warrant [Member]
Secured debt	$ 15,160,000		$ 15,160,000

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)			6 Months Ended
	Mar. 13, 2023	Jan. 08, 2021	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized			5,000,000		5,000,000
Preferred stock, par value			$ 0.0001		$ 0.0001
Preferred stock, shares issued			0		0
Preferred stock, shares outstanding			0		0
Common stock, shares authorized			200,000,000		200,000,000
Common stock, par value			$ 0.0001		$ 0.0001
Common stock, shares outstanding			37,951,261		37,949,196
Common stock, shares issued			37,951,261		37,949,196
Warrant to purchase share of common stock			10,357,086
Proceeds from issuance of warrants				$ 178,000
Proceeds from issuance costs	$ 25,000,000
Juvenescence [Member]
Class of Stock [Line Items]
Line of credit facility			$ 2,500,000
Warrant to purchase share of common stock			1,898,489
Juvenescence [Member] | Second Agreement [Member]
Class of Stock [Line Items]
Line of credit facility			$ 1,000,000
Proceeds from issuance of warrants			0
Chardan Capital Markets LLC [Member]
Class of Stock [Line Items]
Common stock, par value		$ 0.0001
Payments for offering		$ 12,600,000
Proceeds from issuance costs			0	$ 0
Series A and B Preferred Stock [Member]
Class of Stock [Line Items]
Extinguishment of debt			$ 36,000,000

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - Equity Incentive Plan [Member] - Employee Stock [Member] shares in Thousands	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for grant, beginning balance	5,139
Number of options outstanding, beginning balance	3,261
Number of RSUs outstanding, beginning balance	3
Weighted average exercise price, outstanding, beginning balance | $ / shares	$ 2.25
Shares available for grant, restricted stock units vested
Number of options outstanding, restricted stock units vested
Number of RSUs outstanding, restricted stock units vested	(3)
Weighted average exercise price, restricted stock units vested | $ / shares
Shares available for grant, ending balance	5,139
Number of options outstanding, ending balance	3,261
Number of RSUs outstanding, ending balance
Weighted average exercise price, outstanding, ending balance | $ / shares	$ 2.25
Number of options outstanding, exercisable, ending balance	3,016
Weighted average exercise price, exercisable, ending balance | $ / shares	$ 2.34

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 35	$ 198	$ 105	$ 437
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	2	8	7	17
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 33	$ 190	$ 98	$ 420

Schedule of Weighted Average As

Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details) - $ / shares	3 Months Ended			6 Months Ended
	Jun. 30, 2023	[1]	Jun. 30, 2022	Jun. 30, 2023	[1]	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Grant Price			$ 0.71			$ 0.79
Market price			$ 0.71			$ 0.79
Expected life (in years)			6 years 29 days			5 years 6 months 29 days
Volatility			128.35%			130.71%
Risk-free interest rates			2.90%			1.74%
Dividend yield
[1]There were no stock options granted under the Plan during the three and six months ended June 30, 2023.

Stock-Based Awards (Details Nar

Stock-Based Awards (Details Narrative)	6 Months Ended
	Jun. 30, 2023 shares
Share-Based Payment Arrangement [Abstract]
Number of common stock reserved	8,500,000
Number of options exercised	0

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income tax provisions	$ 0	$ 0	$ 0	$ 0

Schedule of Non-cash Investing

Schedule of Non-cash Investing and Financing Transactions (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Supplemental Cash Flow Elements [Abstract]
Cash paid during the period for interest	$ 23	$ 12
Issuance of common stock upon vesting of restricted stock units (Note 8)	2	5
Issuance of warrants for debt issuance under the 2020 Loan Agreement		178
Fair value of liability classified warrants at debt inception date (Note 6)	663	3,325
Debt refinanced with new debt (Note 5)		$ 7,160

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)				3 Months Ended		6 Months Ended
	Jul. 24, 2023	May 17, 2023	Apr. 20, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Net loss				$ (2,669,000)	$ (2,618,000)	$ (5,946,000)	$ (5,324,000)
Juvenescence Limited [Member] | Subsequent Event [Member]
Extinguishment of debt	$ 36
Continuing Operations [Member]
Net loss		$ 2,000,000	$ 2,000,000
Segment Continuing Operations One [Member]
Net loss		4,000,000	4,000,000
Segment Continuing Operations Two [Member]
Net loss		$ 6,000,000	$ 6,000,000
Lease Agreement [Member]
Lease and rental expense						$ 844	$ 1,074

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

3 Months Ended

6 Months Ended

Aug. 11, 2023

Aug. 01, 2023

Jul. 31, 2023

Jul. 24, 2023

Jul. 05, 2023

May 09, 2023

Feb. 09, 2023

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

Mar. 31, 2024

Oct. 31, 2023

Mar. 15, 2023

Mar. 13, 2023

Dec. 31, 2022

Mar. 30, 2020

Subsequent Event [Line Items]

Secured debt

$ 10,000,000

$ 10,000,000

Secured note amendments

$ 105,000,000

Preferred stock, shares authorized

5,000,000

5,000,000

5,000,000

Stockholders equity

$ (22,175,000)

$ (22,175,000)

$ (17,212,000)

Preferred stock voting rights

(i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock.

Research grant award

160,000

$ 259,000

$ 334,000

$ 655,000

Juvenescence Limited [Member] | Forecast [Member] | Secured Convertible Promissory Note [Member]

Subsequent Event [Line Items]

Line of credit, current borrowing capacity

$ 10,000,000

2020 Loan Agreement [Member]

Subsequent Event [Line Items]

Line of credit, current borrowing capacity

$ 3,000,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Secured debt

$ 10,000,000

Converted into preferred stock

36,939,190

Conversion percentage, description

(y) February 1, 2024, provided that such conversion is not limited by the 19.9% Cap or the 50% Cap as described below; and if Automatic Conversion would then be limited by the 19.9% Cap or the 50% Cap, the Automatic Conversion shall take place on the tenth day after such stockholder approvals have been obtained as may be required to permit such Automatic Conversion without the limitations of the 19.9% Cap and the 50% Cap. Further, if the holders of at least a majority of the outstanding shares of Series B Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, and the conversion is not then limited by the 19.9% Cap or the 50% Cap, then the outstanding shares of Series B Preferred Stock shall be converted into common stock upon such approval or consent.

Research grant award

$ 341,000

Subsequent Event [Member] | Series B Preferred Stock [Member]

Subsequent Event [Line Items]

Shares issued upon conversion

13,060,809

Subscriptions price

$ 100,000

Preferred stock closing price

$ 0.72

Conversion percentage, description

If under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of common stock in excess of the “19.9% Cap” upon any conversion of Series B Preferred Stock, then unless and until such stockholder approval has been obtained, the maximum number of shares of common stock that may be issued upon conversion of all shares of Series B Preferred Stock shall be an amount equal to the 19.9% Cap. The 19.9% Cap means 7,550,302 shares of common stock, which is 19.9% of the shares of common stock outstanding on February 14, 2022 when the Secured Note, a portion of which has not been approved by AgeX stockholders for conversion into common stock without regard to the 19.9% Cap and 50% Cap, was issued.

Subsequent Event [Member] | Juvenescence [Member]

Subsequent Event [Line Items]

Secured debt

$ 10,000,000

Subsequent Event [Member] | Juvenescence Limited [Member]

Subsequent Event [Line Items]

Secured debt

$ 10,000,000

Extinguishment of debt

36

Stockholders equity

$ 6,000,000

Subsequent Event [Member] | Juvenescence Limited [Member] | Series A Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, shares authorized

211,600

Subsequent Event [Member] | Juvenescence Limited [Member] | Series B Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, shares authorized

148,400

Subsequent Event [Member] | Fourth Amendment [Member]

Subsequent Event [Line Items]

Debt conversion description

(i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bio, and (ii) Juvenescence may convert the outstanding amount of the Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion. The 19.9% Cap is a provision of the Secured Note that limits the amount of common stock that Juvenescence may acquire through the conversion of Secured Note loans in order to comply with NYSE American requirements pertaining to the amount of shares that a listed company, such as AgeX, may sell at a price less than the market prices prevailing at the time the loans were made (the “Drawdown Market Prices”) without shareholder approval.

Subsequent Event [Member] | 2020 Loan Agreement [Member] | Juvenescence Limited [Member]

Subsequent Event [Line Items]

Secured debt

$ 10,000,000

Secured Convertible Promissory Note [Member]

Subsequent Event [Line Items]

Remaining in line of credit

$ 4,000,000

$ 2,000,000

3,500,000

Secured note amendments

25,000,000

Secured Convertible Promissory Note [Member] | Juvenescence [Member]

Subsequent Event [Line Items]

Secured note amendments

$ 10,000,000

$ 10,000,000

$ 10,000,000

Secured Convertible Promissory Note [Member] | Juvenescence Limited [Member]

Subsequent Event [Line Items]

Line of credit, current borrowing capacity

$ 10,000,000

Secured note amendments

$ 5,000,000

Secured Convertible Promissory Note [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Remaining in line of credit

$ 500,000

$ 500,000

Serina Note [Member] | Juvenescence Limited [Member] | Forecast [Member]

Subsequent Event [Line Items]

Secured note amendments

$ 10,000,000

Origination Fee [Member] | Subsequent Event [Member] | Juvenescence Limited [Member]

Subsequent Event [Line Items]

Secured debt

$ 10,000,000